Matches in SemOpenAlex for { <https://semopenalex.org/work/W2343550096> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2343550096 endingPage "573" @default.
- W2343550096 startingPage "565" @default.
- W2343550096 abstract "Graded challenges are the criterion standard for evaluating adverse drug reactions (ADR). Evidence-based guidelines regarding the optimal number of steps for challenges are lacking.To determine the safety and outcomes of 1- or 2-step test doses among patients with ADRs seen by the allergy/immunology consult service and to compare the outcomes of 1- or 2-step test doses with multistep challenges performed during the same time period.We conducted a retrospective chart review of all 1- or 2-step test doses and multistep challenges at a single academic center between 2008 and 2013. Patient demographics, symptoms of initial ADRs, and outcomes of test doses and multistep challenges were reviewed. ADRs were classified by type and were graded by severity. Outcomes of 1- or 2-step test doses were compared with multistep challenges.We identified 456 patients who underwent 497 one- or 2-step test doses (mean age, 51 years; 67.5% female patients). The most common drugs that prompted test doses were β-lactams (62%). The majority of patients (n = 444 [89%]) did not experience any ADRs during test doses. ADRs that occurred during test doses (n = 53 [11%]) were most commonly non-immune-mediated (45%) or IgE-mediated (32%), with grade 1 or 2 severity (100%). Forty-nine percent of ADRs during test doses did not receive any treatment. The ADR rate during multistep challenges (10/82 [12%]) was similar to test doses.One- or 2-step test doses were safe for evaluation of ADRs. Multistep challenges did not confer added safety. Furthermore, 1- or 2-step test doses did not raise concern for induction of tolerance." @default.
- W2343550096 created "2016-06-24" @default.
- W2343550096 creator A5013216567 @default.
- W2343550096 date "1957-03-01" @default.
- W2343550096 modified "2023-09-25" @default.
- W2343550096 title "The Newer Topical Antipruritic Agents" @default.
- W2343550096 cites W1495184715 @default.
- W2343550096 cites W1973537897 @default.
- W2343550096 cites W2038750626 @default.
- W2343550096 cites W2053374282 @default.
- W2343550096 cites W2054423951 @default.
- W2343550096 cites W2075812128 @default.
- W2343550096 cites W2083181142 @default.
- W2343550096 cites W2085771839 @default.
- W2343550096 cites W2087017141 @default.
- W2343550096 cites W2090341945 @default.
- W2343550096 cites W2091685656 @default.
- W2343550096 cites W2098527499 @default.
- W2343550096 cites W2132821145 @default.
- W2343550096 cites W2169980890 @default.
- W2343550096 cites W2395603159 @default.
- W2343550096 cites W2397635773 @default.
- W2343550096 cites W2413390511 @default.
- W2343550096 cites W2413453897 @default.
- W2343550096 cites W2422790457 @default.
- W2343550096 cites W2461905154 @default.
- W2343550096 cites W2465642230 @default.
- W2343550096 doi "https://doi.org/10.1016/s0025-7125(16)34455-8" @default.
- W2343550096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13407236" @default.
- W2343550096 hasPublicationYear "1957" @default.
- W2343550096 type Work @default.
- W2343550096 sameAs 2343550096 @default.
- W2343550096 citedByCount "1" @default.
- W2343550096 crossrefType "journal-article" @default.
- W2343550096 hasAuthorship W2343550096A5013216567 @default.
- W2343550096 hasConcept C126322002 @default.
- W2343550096 hasConcept C151730666 @default.
- W2343550096 hasConcept C197934379 @default.
- W2343550096 hasConcept C203014093 @default.
- W2343550096 hasConcept C207480886 @default.
- W2343550096 hasConcept C2777267654 @default.
- W2343550096 hasConcept C2779060952 @default.
- W2343550096 hasConcept C2780035454 @default.
- W2343550096 hasConcept C71924100 @default.
- W2343550096 hasConcept C86803240 @default.
- W2343550096 hasConcept C98274493 @default.
- W2343550096 hasConceptScore W2343550096C126322002 @default.
- W2343550096 hasConceptScore W2343550096C151730666 @default.
- W2343550096 hasConceptScore W2343550096C197934379 @default.
- W2343550096 hasConceptScore W2343550096C203014093 @default.
- W2343550096 hasConceptScore W2343550096C207480886 @default.
- W2343550096 hasConceptScore W2343550096C2777267654 @default.
- W2343550096 hasConceptScore W2343550096C2779060952 @default.
- W2343550096 hasConceptScore W2343550096C2780035454 @default.
- W2343550096 hasConceptScore W2343550096C71924100 @default.
- W2343550096 hasConceptScore W2343550096C86803240 @default.
- W2343550096 hasConceptScore W2343550096C98274493 @default.
- W2343550096 hasIssue "2" @default.
- W2343550096 hasLocation W23435500961 @default.
- W2343550096 hasLocation W23435500962 @default.
- W2343550096 hasOpenAccess W2343550096 @default.
- W2343550096 hasPrimaryLocation W23435500961 @default.
- W2343550096 hasRelatedWork W2038150255 @default.
- W2343550096 hasRelatedWork W2410715098 @default.
- W2343550096 hasRelatedWork W2411369533 @default.
- W2343550096 hasRelatedWork W2577969911 @default.
- W2343550096 hasRelatedWork W262427624 @default.
- W2343550096 hasRelatedWork W2970951906 @default.
- W2343550096 hasRelatedWork W4226211021 @default.
- W2343550096 hasRelatedWork W4248778187 @default.
- W2343550096 hasRelatedWork W4298839402 @default.
- W2343550096 hasRelatedWork W94679957 @default.
- W2343550096 hasVolume "41" @default.
- W2343550096 isParatext "false" @default.
- W2343550096 isRetracted "false" @default.
- W2343550096 magId "2343550096" @default.
- W2343550096 workType "article" @default.